Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
-$0.19 today
- Market cap
- $859.56M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
Volume 0.99M
Average 1.49M
CRVS Income Before Tax
Profit after all operating and non-operating items but before income tax.
Corvus Pharmaceuticals, Inc.NASDAQ: CRVS
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax turns negative
Q1 FY2026 income before tax was -$13.69M, compared with $15.19M a year earlier. Trailing-twelve-month income before tax was -$44.17M.
Context
- Income before tax grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income before tax holds near -$13.69M or moves back toward the trailing-twelve-month quarterly average of -$11.04M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (15.28M) USD
- Year-over-year change
- +75.5%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.28M) | +75.5% |
| FY2024 | 2024-12-31 | (62.29M) | -130.5% |
| FY2023 | 2023-12-31 | (27.03M) | +34.6% |
| FY2022 | 2022-12-31 | (41.31M) | +4.5% |
| FY2021 | 2021-12-31 | (43.24M) | — |
Income Before Tax vs competitors
How CRVS compares with its peers on the latest reported figures
- Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.7% is the 3rd highest of 9, against a peer median of -28.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.88M USD | +463.6% | — | 48.0% | |
| LTM Jun 2024 | -$32.47M USD | — | — | 3980.4% | |
| LTM Mar 2026 | -$44.17M USD | -6.7% | — | — | |
| FY2025 | -€49.18M EUR | +0.6% | — | 1764.5% | |
| LTM Mar 2026 | -$58.91M USD | -240.8% | — | 165.7% | |
| LTM Mar 2026 | -$68.17M USD | -23.5% | — | — | |
| LTM Mar 2026 | -$71.03M USD | -29.5% | — | 45.2% | |
| LTM Jun 2026 | -$156.74M USD | -27.8% | — | 287.1% | |
| LTM Mar 2026 | -$172.66M USD | -41.8% | — | 368.3% | |
| LTM Jun 2026 | -$452M USD | -47.7% | — | 386.3% | |
| Peer median (excluding CRVS) | — | -28.6% | — | 327.7% | |
Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 105K |
| Gross Profit | 0 | 0 | 0 | 0 | (105K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 29.12M | 24.47M | 16.53M | 19.39M | 33.72M |
| Selling, General & Admin | 9.52M | 8.1M | 6.88M | 8.16M | 9.25M |
| Operating Expenses | 38.63M | 32.57M | 23.41M | 27.55M | 42.87M |
| Depreciation & Amortization | 460K | 367K | 151K | 85K | 105K |
| EBITDA | (42.77M) | (40.94M) | (26.88M) | (62.21M) | (15.18M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (38.63M) | (32.57M) | (23.41M) | (27.55M) | (42.97M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 654K | 1.58M | 1.82M | 2.51M |
| Interest Expense | 15K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (4.61M) | (8.74M) | (3.62M) | (34.75M) | 27.69M |
| Income Before Tax | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (0.89) | (0.56) | (1.02) | (0.19) |
| EPS (Diluted) | (1.03) | (0.89) | (0.56) | (1.02) | (0.53) |
| Weighted Avg Shares | 41.85M | 46.55M | 48.03M | 60.99M | 78.96M |
| Weighted Avg Shares (Diluted) | 41.85M | 46.55M | 48.03M | 60.99M | 79.74M |
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
Intrinsic Alpha fair value
Locked
Current Price
$10.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.